Interstitial pneumonitis

Fumihiko Hirai, Gouji Toyokawa, Taro Ohba, Hiromoto Kitajima, Masafumi Yamaguchi, Riichiroh Maruyama, Motoharu Hamatake, Takashi Seto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticlepeer-review


The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.

Original languageEnglish
Pages (from-to)1782-1784
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number11
Publication statusPublished - Nov 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Interstitial pneumonitis'. Together they form a unique fingerprint.

Cite this